***Background.*** Oritavancin (ORI) is under regulatory review in the USA and Europe for the treatment of acute bacterial skin and skin structure infections (SSSI) caused by Gram-positive pathogens. The ORI activity was assessed against contemporary isolates causing SSSI.

***Methods.*** 8,428 isolates from documented SSSI were collected from 27 sites in the USA and 34 sites in Europe, Israel and Turkey as part of the SENTRY Antimicrobial Surveillance Program (2012-2013). Bacteria were identified by standard algorithms and MALDI-TOF. Susceptibility testing was performed by CLSI methods (M07-A9); interpretation of MIC results used CLSI (2014) and EUCAST (2014) criteria

***Results.*** ORI had MIC~50/90~ values of 0.03/0.06 µg/ml against *S. aureus*, which were ≥8-fold lower than those obtained for vancomycin (VAN; MIC~50/90~, 1/1 µg/ml), daptomycin (DAP; MIC~50/90~, 0.25/0.5 µg/ml) or linezolid (LZD; MIC~50/90~, 1/1 µg/ml). These agents had equivalent MIC~50/90~ values against methicillin-susceptible (MSSA) and -resistant *S. aureus* (MRSA). ORI MIC~50/90~ values against coagulase-negative staphylococci (CoNS; MIC~50/90~, 0.03/0.06 µg/ml) were ≥8-fold lower than comparators. VanA-phenotype *E. faecalis* had ORI MIC values (MIC~50/90~, 0.25/0.5 µg/ml) 16-fold higher than those obtained for VAN-susceptible isolates (MIC~50/90~, 0.015/0.03 µg/ml); nevertheless, ORI was ≥2-fold more active than DAP (MIC~50/90~, 0.5/1 µg/ml) or LZD (MIC~50/90~, 1/1 µg/ml) against VanA *E. faecalis*. ORI (MIC~50/90~, 0.004/0.008 µg/ml) had equivalent MIC values against VanB and VAN-susceptible *E. faecium* and higher MIC values (MIC~50/90~, 0.03/0.12 µg/ml) against VanA strains. However, ORI MIC values against VanA *E. faecium* were 8- to -64 lower than active (100% susceptible) comparators (DAP, MIC~50/90~, 2/4 µg/ml; and LZD, MIC~50/90~, 1/1 µg/ml)*.* ORI had potent activity against *S. pyogenes* (MIC~50/90~, 0.03/0.12 µg/ml), *S. agalactiae* (MIC~50/90~, 0.03/0.06 µg/ml) and the *S. anginosus* group (MIC~50/90~, 0.008/0.015 µg/ml), with slightly higher MIC results against *S. dysgalactiae* (MIC~50/90~, 0.06/0.25 µg/ml)*.*

***Conclusion.*** ORI had potent activity *in vitro* against this contemporary collection of Gram-positive isolates causing SSSI. These results benchmark ORI activity prior to becoming clinically available.
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